

## OVERVIEW•Catalyst

- Summary

## EXECUTIVE SUMMARY•Strategic scoping and focus

- Datamonitor key findings

## PRODUCT OVERVIEW•Key marketed and pipeline products•Datamonitor's assessment summary

### MARKETED PRODUCT PROFILES•Yervoy (ipilimumab; Bristol-Myers Squibb)•Drug profile

- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness

### •Zelboraf (vemurafenib; Roche/Daiichi Sankyo)•Drug profile

- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness

### •Other drugs ◦DTIC-Dome (dacarbazine; Bayer) and generic dacarbazine

- Temodar (temozolomide; Merck & Co.)
- Interleukin-2

### PIPELINE PRODUCT PROFILES•Dabrafenib (GSK-2118436; GlaxoSmithKline)•Drug overview

- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness

### •Trametinib (GSK-1120212; GlaxoSmithKline)•Drug overview

- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness

### •Abraxane (albumin-bound paclitaxel; Celgene)•Drug overview

- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness

### •Allovetin-7 (velimogene aliplasimid; Vical)•Drug overview

- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness

### •MAGE-A3 ASCI (astuprotimut-r; GlaxoSmithKline)•Drug overview

- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness

### •OncoVEX GM-CSF (talimogene laherparepvec; Amgen)•Drug overview

- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness

### •POL-103A (Polynoma/CK Life Sciences)•Drug overview

- Drug profile

- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness

- Masitinib (AB-1010; AB Science)◦Drug overview
- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness

#### BIBLIOGRAPHY•Journal papers

- Websites
- Datamonitor reports

#### APPENDIX•Market definition

- PharmaVitae Explorer database
- Contributing experts
- Report methodology

#### TABLES•Table: Key marketed drugs for melanoma, 2012

- Table: Key pipeline drugs for melanoma, 2012
- Table: Yervoy – drug profile, 2012
- Table: Overview of major melanoma approvals for Yervoy
- Table: Overview of pivotal trial data for Yervoy in melanoma, 2012
- Table: Datamonitor drug assessment summary of Yervoy for melanoma, 2012
- Table: Zelboraf – drug profile, 2012
- Table: Overview of major melanoma approvals for Zelboraf
- Table: Overview of pivotal trial data for Zelboraf in melanoma, 2012
- Table: Datamonitor drug assessment summary of Zelboraf for melanoma, 2012
- Table: Dacarbazine – drug profile, 2012
- Table: Temodar – drug profile, 2012
- Table: Interleukin-2 – drug profile, 2012
- Table: Dabrafenib – drug profile, 2012
- Table: Clinical development of dabrafenib in melanoma, 2012
- Table: Summary of Phase II clinical trial data for dabrafenib in melanoma
- Table: Ability of dabrafenib to meet unmet needs in melanoma, 2012
- Table: Datamonitor drug assessment summary of dabrafenib for melanoma, 2012
- Table: Trametinib – drug profile, 2012
- Table: Clinical development of trametinib in melanoma, 2012
- Table: Summary of Phase II clinical trial data for trametinib in melanoma
- Table: Ability of trametinib to meet unmet needs in melanoma, 2012
- Table: Datamonitor drug assessment summary of trametinib for melanoma, 2012
- Table: Abraxane – drug profile, 2012
- Table: Clinical development of Abraxane in melanoma, 2012
- Table: Summary of Phase II clinical trial data for Abraxane in melanoma
- Table: Ability of Abraxane to meet unmet needs in melanoma, 2012
- Table: Datamonitor drug assessment summary of Abraxane for melanoma, 2012
- Table: Allovectin-7 – drug profile, 2012
- Table: Clinical development of Allovectin-7 in melanoma, 2010
- Table: Ability of Allovectin-7 to meet unmet needs in melanoma, 2012
- Table: Datamonitor drug assessment summary of Allovectin-7 for melanoma, 2012
- Table: MAGE-A3 ASCI – drug profile, 2012
- Table: Clinical development of MAGE-A3 ASCI in melanoma, 2012
- Table: Datamonitor drug assessment summary of MAGE-A3 ASCI for melanoma, 2012
- Table: OncoVEX GM-CSF – drug profile, 2012
- Table: Clinical development of OncoVEX GM-CSF in melanoma, 2012
- Table: Ability of OncoVEX GM-CSF to meet unmet needs in first-line metastatic melanoma, 2012
- Table: Datamonitor drug assessment summary of OncoVEX GM-CSF for melanoma, 2012
- Table: POL-103A – drug profile, 2012
- Table: Clinical development of POL-103A, 2012
- Table: Datamonitor drug assessment summary of POL-103A for melanoma, 2012
- Table: Masitinib – drug profile, 2012
- Table: Clinical development of masitinib, 2012
- Table: Datamonitor drug assessment summary of masitinib for melanoma, 2012
- Table: Summary of therapeutic classes in melanoma by ATC code, 2012

FIGURES•Figure: Datamonitor's drug assessment summary of key marketed and pipeline drugs for melanoma, 2012

- Figure: Yervoy's SWOT analysis for melanoma, 2012
- Figure: Datamonitor's drug assessment summary of Yervoy for melanoma, 2012
- Figure: Zelboraf's SWOT analysis for melanoma, 2012
- Figure: Datamonitor's drug assessment summary of Zelboraf for melanoma, 2012
- Figure: Phase III results for first-line dabrafenib in metastatic melanoma
- Figure: Dabrafenib's SWOT analysis for melanoma, 2012
- Figure: Datamonitor's drug assessment summary of dabrafenib for melanoma, 2012
- Figure: Phase III results for first- or second-line trametinib in metastatic melanoma
- Figure: Trametinib's SWOT analysis for melanoma, 2012
- Figure: Datamonitor's drug assessment summary of trametinib for melanoma, 2012
- Figure: Phase II results for first-line and second-line Abraxane in metastatic melanoma
- Figure: Abraxane's SWOT analysis for melanoma, 2012
- Figure: Datamonitor's drug assessment summary of Abraxane for melanoma, 2012
- Figure: Phase II results for second-line Allovectin-7 in metastatic melanoma, 2010
- Figure: Allovectin-7's SWOT analysis for melanoma, 2012
- Figure: Datamonitor's drug assessment summary of Allovectin-7 for melanoma, 2012
- Figure: Phase II results for MAGE-A3 ASCI in combination with two different adjuvant systems
- Figure: MAGE-A3 ASCI's SWOT analysis for melanoma, 2012
- Figure: Datamonitor's drug assessment summary of MAGE-A3 ASCI for melanoma, 2012
- Figure: Phase II results for second-line OncoVEX GM-CSF monotherapy for unresectable Stage IIIc and IV melanoma
- Figure: OncoVEX GM-CSF's SWOT analysis for melanoma, 2012
- Figure: Datamonitor's drug assessment summary of OncoVEX GM-CSF for melanoma, 2012
- Figure: Phase II results for adjuvant POL-103A in melanoma, 2012
- Figure: POL-103A's SWOT analysis for melanoma, 2011
- Figure: Datamonitor's drug assessment summary of POL-103A for melanoma, 2012
- Figure: Masitinib's SWOT analysis for melanoma, 2012
- Figure: Datamonitor's drug assessment summary of masitinib for melanoma, 2012
- Figure: The PharmaVitae Explorer